2-(4-((2-morpholinopyrimidin-4-yl)oxy)naphthalen-1-yl)-2-oxoacetyl chloride | 1245918-65-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-((2-morpholinopyrimidin-4-yl)oxy)naphthalen-1-yl)-2-oxoacetyl chloride
• CAS: 1245918-65-3
• 化学式: C₂₀H₁₆ClN₃O₄
• 分子量: 397.818
• InChiKey: XQKSSGLUSLQUQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  28.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  81.62
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide 、 2-(4-((2-morpholinopyrimidin-4-yl)oxy)naphthalen-1-yl)-2-oxoacetyl chloride 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide
  参考文献：
  名称：

  Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site

  摘要：

  We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.102
• 作为产物：
  描述：

  [4-(2-morpholin-4-yl-pyrimidin-4-yl-oxy)-naphthalen-1-yl]-oxo-acetic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(4-((2-morpholinopyrimidin-4-yl)oxy)naphthalen-1-yl)-2-oxoacetyl chloride
  参考文献：
  名称：

  Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site

  摘要：

  We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.102